Regenerative stem cell therapy for stroke in Europe (RESSTORE): a multicenter randomized controlled efficacy clinical trial.

Fiche publication

Date publication

septembre 2024

Journal

Frontiers in stroke

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MOULIN Thierry

Tous les auteurs :
Legris L, Moisan A, Jaillard A, Bonnet L, Moulin T, Sibon I, Touzé E, Favre-Wiki I, Cordonnier C, Dellaschiava L, Mazighi M, Rosso C, Alamowitch S, Calvet D, Barbieux-Guillot M, Roux S, Mojallal AA, Boucher F, Thuriot A, Soulard J, Naegele B, Perennou D, Roustit M, Putkaradze Z, Hommel M, Lehmann A, Colombat J, Chorfa F, Maucort-Boulch D, Lamalle L, Grand S, Krainik A, Detante O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41542240

Résumé

Encouraging the activation of brain repair mechanisms and fostering spontaneous functional recovery in stroke patients hold great promise for alleviating the global burden of this condition and allowing an extended therapeutic time window. Cell-based regenerative therapy (with mesenchymal stem/stromal cells, such as adipose-derived stem cells [ADSCs]) is particularly attractive considering its excellent safety profile, low immunogenicity after allogeneic application, and well-established functional benefits on stroke recovery in animal models. This study aims to assess the efficacy and safety effects of intravenous (IV) infusion of freshly cultured allogeneic ADSCs on recovery after ischemic stroke.